Cadila Healthcare is currently trading at Rs. 442.05, up by 12.60 points or 2.93% from its previous closing of Rs. 429.45 on the BSE.
The scrip opened at Rs. 446.00 and has touched a high and low of Rs. 450.00 and Rs. 438.60 respectively. So far 3,19,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 450.00 on 17-Feb-2017 and a 52 week low of Rs. 305.00 on 12-Apr-2016.
Last one week high and low of the scrip stood at Rs. 450.00 and Rs. 356.30 respectively. The current market cap of the company is Rs. 45,269.90 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.18% and 8.03% respectively.
Cadila Healthcare has received US Food and Drug Administration (USFDA) clearance for its Gujarat plant after an inspection. The USFDA inspected company’s Moraiya facility from February 6, 2017 to February 15, 2017. At the end of the inspection, no observation (483) has been issued.
Earlier, USFDA had issued a warning letter to the Cadila’s facility at Moraiya in Gujarat for breach of good manufacturing practices.
Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.
